A MESSAGE FROM THE CEO
In the last decade, we have been at the centre of Cardio-metabolic care in Nigeria through the introduction of therapeutics, point-of-care diagnostics for Diabetes, Hypertension and Heart diseases, and Rapid diagnostic test kits. At the time of inception, we introduced one product to market which was Glucodix (our brand of Metformin). In the last 9 years, Codix has experienced tremendous growth, as demonstrated by a growing market share and product portfolio. As we look at what we have accomplished over the years and what lies ahead, we believe that the next 20 years for us will be even brighter.
Our success story as a company stems from our contributions to the building and development of the health service (a major part of our role in the market place) by being involved in the development of guidelines, creating patient pathways, strategy formulations and capacity building in the areas of our interest (Diabetes, Hypertension and Heart disease). We facilitated the development of the Lagos State Guideline/Protocol for diabetes management, which was rolled out to both state and private hospitals in Lagos State in 2010. We were also at the forefront of facilitating the use of Glycosylated haemoglobin (HbA1c) for clinical diagnosis of Diabetes. We contributed to developing the HbA1c market through trainings, clinical meetings and stakeholder engagements for Diabetes Association of Nigeria (DAN), Endocrine and Metabolism Society of Nigeria (EMSON) and consultant endocrinologists across the country, along with several donations of the machine all towards emphasizing the importance of HbA1c – Diagnosis of diabetes and estimation of risk of the occurrence/onset of deadly complications due to diabetes.
Our success story as a company stems from our contributions to the building and development of the health service
In the public sector, we have partnered with the Ogun state Ministry of Health, Lagos state Ministry of Health and Oyo state Ministry of Health to provide training and support in running dedicated Cardio-metabolic care clinics. In the private sector, we partnered with the Support to National Malaria Program (SuNMap) in ensuring access to Malaria Rapid Diagnostic Test kits (mRDTs) in the private sector (across pharmacies and PPMVs) during which we trained up to 5,000 patient care givers/pharmacies, etc, Clinton Health Access Initiative (CHAI) and we are growing our partnerships in the private sector on pharmaceutical services and other well-meaning NGOs like Family Care international, Africare, Livewell initiative, etc. We have also engaged in CSR projects in partnership with charity groups such as Christian Aid and carried out mass screenings in different locations Free of Charge.
We pride ourselves in being able to chart new courses like taking diagnosis from the lab to the doctor’s table (point-of-care diagnosis), which the industry was previously sceptical about. Empowering patients to be responsible for the management of the disease by ensuring access to affordable glucometers and strips.
Our Outlook For The Future:
We aim to have established local presence through partnerships in all 5 English-speaking West African countries (Gambia and Liberia in addition to Nigeria, Ghana and Sierra Leone) by the end of the year 2021. In addition, by the end of the year 2030 our goal is to have expanded to other parts of West Africa, further establishing our presence in the French speaking countries of the region.
It is our vision to localize as many of the products we currently do starting with Blood Glucose Meters. Also, we intend to have technological transfer partnerships with our current partners, to have localized production for products we currently import starting with Blood Glucose Meters and strips by 2021. It would be the first in the Sub-Saharan African Continent.
We plan to expand into nutraceuticals and wellness products particularly those that fit into our Cardio-metabolic care business.
We thank you for your continued support of Codix, and we look forward to sharing news of even greater achievements in future.
Managing Director/Chief Executive Officer
Codix Pharma Ltd.